Clinical Trial: A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07862998) titled 'A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy' on Oct. 02.

Brief Summary: The purpose of this study is to confirm the efficacy and safety of pemigatinib in participants with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 fusion or rearrangements after at least 1 prior line of systemic therapy.

Study Start Date: Dec. 15

Study Type: INTERVENTIONAL

Condition: Unresectable Cholangiocarcinoma Advanced/Metastatic Cholangiocar...